PUBLISHER: Grand View Research | PRODUCT CODE: 1433657
PUBLISHER: Grand View Research | PRODUCT CODE: 1433657
The global platelet aggregation devices market is expected to reach USD 1.18 billion by 2030 exhibiting a CAGR of 5.6% during the forecast period, according to a new report by Grand View Research, Inc. The growth is attributed to the increasing burden of chronic diseases such as heart disease and strokes. These conditions account for many global deaths, necessitating precise diagnostic and management tools. These devices are pivotal in assessing these conditions since platelet function is crucial in clot formation and blood vessel health.
Furthermore, advancements in healthcare technology have led to the development of more advanced and accurate platelet aggregation devices, meeting the growing demand for cutting-edge technology in the sector. For instance, in July 2022, Werfen launched GEMweb Live, an onscreen viewer for cardiac surgery test results, aiding in care decisions during cardiovascular procedures, with integration for platelet function monitoring. This digital solution can improve efficiency and guide clinical decisions during cardiovascular surgeries, potentially increasing the demand for platelet aggregation devices and related diagnostic tools in hospital acute care settings.
Healthcare policies and regulations further drive market growth when favorable while increasing awareness of disorders among healthcare professionals and the general population enhances the demand for these products. The prevalence of hereditary bleeding disorders such as hemophilia A, hemophilia B, and von Willebrand disease underscores the importance in managing such conditions effectively. Moreover, these devices play a crucial role in supporting critical clinical assessments and monitoring, which is contributing to the market's growth.
As healthcare systems continue to evolve and highlight the importance of accurate diagnostics and patient monitoring, the demand for platelet aggregation devices is on the rise. Additionally, the surge in R&D activities is driving innovation in platelet aggregation devices, making them increasingly relevant in modern healthcare. R&D efforts aim to enhance device sensitivity, specificity, and customization, allowing for more precise diagnostics across a wide range of health conditions.
Furthermore, platelet aggregation devices market players are undertaking strategic initiatives to address the growing demand for efficient and effective manufacturing capacity. Players are focusing on developing new products, clinical research, and innovation to strengthen their position. For instance, in June 2022, Sysmex America's XN-10 Automated Hematology Analyzer with Blood Bank mode received FDA clearance for residual white blood cell counting, a first in automated hematology analyzers. It provides efficient and accurate cell counts for blood component quality in transfusion medicine and blood product manufacturing. Such initiatives are expected to propel the overall growth of platelet aggregation devices market.